Fred Hutch spinout SEngine Precision Medicine raises $5.1M Series A to commercialize PARIS tumor‑testing platform

SEngine Precision Medicine raised $5.1 million to commercialize its PARIS platform, which grows patients’ tumor cells in the lab to test safety and effectiveness of over 200 drugs or drug combinations and help match cancer patients to therapies. The company also gathers data for drug discovery, has a joint venture with Atomwise, and completed a Series A led by the Bangarang Group.

No comments yet.

Also discussed on the What Fuels You podcast